Advocacy Wealth Management Services’s Juno Therapeutics, Inc. JUNO Stock Holding History

Advocacy Wealth Management Services’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-400	Closed	-$18K	–	224
2017 Q4	$18K	Hold	400	–	–	0.01%	119
2017 Q3	$18K	Hold	400	–	–	0.01%	144
2017 Q2	$12K	Hold	400	–	–	﹤0.01%	176
2017 Q1	$9K	Hold	400	–	–	﹤0.01%	223
2016 Q4	$8K	Hold	400	–	–	﹤0.01%	227
2016 Q3	$12K	Hold	400	–	–	﹤0.01%	257
2016 Q2	$15K	Hold	400	–	–	0.01%	273
2016 Q1	$15K	Hold	400	–	–	0.01%	325
2015 Q4	$18K	Buy	+400	New	+$19.8K	0.02%	282

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

Advocacy Wealth Management Services's JUNO Position: Q1 2018 in Review

Advocacy Wealth Management Services sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 400 shares — an estimated $18K sold.

Advocacy Wealth Management Services first reported a position in JUNO in Q4 2015 and held it in 9 quarters. The position peaked at $18K in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Advocacy Wealth Management Services reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Advocacy Wealth Management Services sold 400 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $18K.
Advocacy Wealth Management Services first reported a position in Juno Therapeutics, Inc. in Q4 2015 and held it in 9 quarters.
Advocacy Wealth Management Services's Juno Therapeutics, Inc. position peaked at $18K in Q4 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Advocacy Wealth Management Services's 13F filing for Q1 2018, filed 12 Apr 2018.